130 related articles for article (PubMed ID: 38366873)
1. Design, Synthesis and In-Silico Studies of Piperidine-Dihydropyridine Hybrids as Anticancer Agents.
Rejinthala S; Endoori S; Thumma V; Mondal T
Chem Biodivers; 2024 Apr; 21(4):e202301456. PubMed ID: 38366873
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, photophysical properties, anticancer evaluation, and molecular docking studies of new pyrimidine linked 4-arylidene-thiazolidin-4-ones as potent anticancer agents.
Jame R
Luminescence; 2024 Jan; 39(1):e4672. PubMed ID: 38286597
[TBL] [Abstract][Full Text] [Related]
3. Development of 1,5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation.
Soltan OM; Abdel-Aziz SA; Sh Shaykoon M; Osawa K; Narumi A; Abdel-Aziz M; Shoman ME; Konno H
Bioorg Med Chem Lett; 2024 Apr; 102():129673. PubMed ID: 38408511
[TBL] [Abstract][Full Text] [Related]
4. Identification of new 5-(2,6-dichlorophenyl)-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-7-carboxylic acids as p38α MAPK inhibitors: Design, synthesis, antitumor evaluation, molecular docking and in silico studies.
El-Wakil MH; El-Dershaby HA; Ghazallah RA; El-Yazbi AF; Abd El-Razik HA; Soliman FSG
Bioorg Chem; 2024 Apr; 145():107226. PubMed ID: 38377818
[TBL] [Abstract][Full Text] [Related]
5. Four-component synthesis of 1,2-dihydropyridine derivatives and their evaluation as anticancer agents.
Abdel-Fattah MA; El-Naggar MA; Rashied RM; Gary BD; Piazza GA; Abadi AH
Med Chem; 2012 May; 8(3):392-400. PubMed ID: 22530887
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
7. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
8. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-
Ismail MA; Abusaif MS; El-Gaby MSA; Ammar YA; Ragab A
RSC Adv; 2023 Apr; 13(18):12589-12608. PubMed ID: 37101951
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
10. Anti-lung Cancer Activity of Synthesized Substituted 1,4-Benzothiazines: An Insight from Molecular Docking and Experimental Studies.
Amin A; Khazir ZU; Ji A; Bhat BA; Murtaza D; Hurrah AA; Bhat IA; Parveen S; Nisar S; Sharma PK
Anticancer Agents Med Chem; 2024; 24(5):358-371. PubMed ID: 37957911
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and in-vitro anti-proliferative with antimicrobial activity of new coumarin containing heterocycles hybrids.
Abdelaziz E; El-Deeb NM; Zayed MF; Hasanein AM; El Sayed IE; Elmongy EI; Kamoun EA
Sci Rep; 2023 Dec; 13(1):22791. PubMed ID: 38123695
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
13. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, Molecular Docking, and Biological Evaluation of Pyrazole Hybrid Chalcone Conjugates as Potential Anticancer Agents and Tubulin Polymerization Inhibitors.
Alam MJ; Alam O; Perwez A; Rizvi MA; Naim MJ; Naidu VGM; Imran M; Ghoneim MM; Alshehri S; Shakeel F
Pharmaceuticals (Basel); 2022 Feb; 15(3):. PubMed ID: 35337078
[TBL] [Abstract][Full Text] [Related]
15. Novel ferrocenylbisphosphonate hybrid compounds: Synthesis, characterization and potent activity against cancer cell lines.
Anusionwu CG; Aderibigbe BA; Adeyemi SA; Ubanako P; Oselusi SO; Choonara YE; Yangkou Mbianda X
Bioorg Med Chem; 2022 Mar; 58():116652. PubMed ID: 35180594
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and molecular docking of novel pyrazole-chalcone analogs of lonazolac as 5-LOX, iNOS and tubulin polymerization inhibitors with potential anticancer and anti-inflammatory activities.
Ahmed AHH; Mohamed MFA; Allam RM; Nafady A; Mohamed SK; Gouda AE; Beshr EAM
Bioorg Chem; 2022 Dec; 129():106171. PubMed ID: 36166898
[TBL] [Abstract][Full Text] [Related]
17. Computational Design, Synthesis, and Bioevaluation of 2-(Pyrimidin-4-yl)oxazole-4-carboxamide Derivatives: Dual Inhibition of EGFR
Raghunath Khedkar N; Sindkhedkar M; Joseph A
Bioorg Chem; 2024 Feb; 143():107027. PubMed ID: 38096682
[TBL] [Abstract][Full Text] [Related]
18. Pyridine-derived VEGFR-2 inhibitors: Rational design, synthesis, anticancer evaluations, in silico ADMET profile, and molecular docking.
Saleh NM; Abdel-Rahman AA; Omar AM; Khalifa MM; El-Adl K
Arch Pharm (Weinheim); 2021 Aug; 354(8):e2100085. PubMed ID: 33948983
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, In Vitro Anticancer Evaluation and Molecular Modelling Studies of 3,4,5-Trimethoxyphenyl-Based Derivatives as Dual EGFR/HDAC Hybrid Inhibitors.
Ibrahim TS; Malebari AM; Mohamed MFA
Pharmaceuticals (Basel); 2021 Nov; 14(11):. PubMed ID: 34832959
[TBL] [Abstract][Full Text] [Related]
20. Novel 1,3-Thiazole Analogues with Potent Activity against Breast Cancer: A Design, Synthesis, In Vitro, and In Silico Study.
Salem MG; El-Maaty DMA; El-Deen YIM; Elesawy BH; Askary AE; Saleh A; Saied EM; Behery ME
Molecules; 2022 Jul; 27(15):. PubMed ID: 35956848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
